In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 2, 2005, Pages 143-150

  Langer, Oliver ^a   Brunner, Martin ^a   Zeitlinger, Markus ^a   Ziegler, Sophie ^a   Müller, Ulrich ^a   Dobrozemsky, Georg ^a   Lackner, Edith ^a   Joukhadar, Christian ^a   Mitterhauser, Markus ^a   Wadsak, Wolfgang ^a   Minar, Erich ^a   Dudczak, Robert ^a   Kletter, Kurt ^a   Müller, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ciprofloxacin; Fluorine 18; Human; Infection imaging; Positron emission tomography

Indexed keywords

CIPROFLOXACIN F 18; DNA TOPOISOMERASE (ATP HYDROLYSING); FLUORINE 18; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRACER; UNCLASSIFIED DRUG;

AGED; ARTICLE; BACTERIAL CELL; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; CONCENTRATION (PARAMETERS); DRUG BINDING; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN TISSUE; IMAGING SYSTEM; LEG INJURY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; SIDE EFFECT; SOFT TISSUE;

AGED; BACTERIAL INFECTIONS; CIPROFLOXACIN; ESCHERICHIA COLI; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; METABOLIC CLEARANCE RATE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 13844270586     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1646-2     Document Type: Article

References (24)

1. Corstens FHM, van der Meer JWM. Nuclear medicine's role in infection and inflammation. Lancet 1999;354:765-70.
2. 99mTc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet 1996;347:233-5.
3. 99mTc-Infecton, a novel agent for detecting sites of infection. J Clin Pathol 1998;51:215-9.
4. Welling MM, Paulusma-Annema A, Balter HS, Pauwels EKJ, Nibbering PH. Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nucl Med 2000;27:292-301.
5. 99mTc- antimicrobial peptides: promising candidates for infection imaging. Q J Nucl Med 2003;47:238-45
6. Das SS, Hall AV, Wareham DW, Britton KE. Infection imaging with radiopharmaceuticals in the 21st century. Braz Arch Biol Technol 2002;45:25-37.
7. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol 1999;2:504-8.
8. Gau W, Kurz J, Petersen U, Ploschke HJ, Wuensche C. Isolation and structural elucidation of urinary metabolites of ciprofloxacin. Arzneimittelforschung 1986;36:1545-9.
9. Langer O, Mitterhauser M, Brunner M, Zeitlinger M, Wadsak W, Mayer BX, et al. Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nucl Med Biol 2003;30:285-91.
10. Langer O, Mitterhauser M, Wadsak W, Brunner M, Müller U, Kletter K, Müller M. A general method for the fluorine-18 labelling of fluoroquinolone antibiotics. J Labelled Comp Radiopharm 2003;46:715-27.
11. 18F]Ciprofloxacin, a new PET tracer for non-invasive assessment of ciprofloxacin tissue pharmacokinetics in humans. Antimicrob Agents Chemother 2004;48(10):in press.
12. National Committee for Clinical Laboratory Standards. MIC testing. NCCLS 2001; Supplemental tables: M100-S111 (M107).
13. Ricci V, Piddock LJ. Accumulation of norfloxacin by Bacteroides fragilis. Antimicrob Agents Chemother 2000;44:2361-6.
14. Shen LL. Molecular mechanisms of DNA gyrase inhibition by quinolone antibacterials. Adv Pharmacol 1994;29A:285-304.
15. 99mTc-ciprofloxacin (Infecton). J Clin Pathol 2002;55:817-23.
16. Bounds SJ, Walters JD, Nakkulka RJ. Fluoroquinolone transport by human monocytes: characterization and comparison to other cells of myeloid lineage. Antimicrob Agents Chemother 2000;44:2609-14.
17. Walters JD, Zhang F, Nakkulka RJ. Mechanisms of fluoroquinolone transport by human neutrophils. Antimicrob Agents Chemother 1999;43:2710-5.
18. Brunner M, Stass H, Möller JG, Schrolnberger C, Erovic B, Hollenstein U, Zeitlinger M, Eichler HG, Müller M. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 2002;46:3724-30.
19. Mortimer PGS, Piddock LJV. A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother 1991;28:639-53.
20. Pauwels EKJ, Welling MM, Lupetti A, Paulusma-Annema A, Nibbering PH, Balter HS. Reply to "Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations [letter to the editor]". Eur J Nucl Med 2000;27:1866-8.
21. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000;31(Suppl 2): S24-8.
22. Britton KE, Vinjamuri S, Hall AV, Solanki K, Siraj QH, Bomanji J, Das S. Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection. Eur J Nucl Med 1997;24:553-6.
23. Joukhadar C, Stass H, Müller-Zellenberg U, Lackner E, Kovar F, Minar E, Müller M. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 2003;47:3099-103.
24. Easmon CSF, Crane JP. Uptake of ciprofloxacin by human neutrophils. J Antimicrob Chemother 1985;16:67-73.